6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2017

Commission file number: 001-36621

FOAMIX PHARMACEUTICALS LTD.

(Translation of registrant's name into English)

2 Holzman Street, Weizmann Science Park

Rehovot, Israel (Address of principal executive office)

_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F S           Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £

CONTENTS

This report on Form 6-K of the registrant consists of (i) a press release issued by the registrant on May 1, 2017, attached hereto as an exhibit and incorporated by reference herein, and (ii) and updated investors presentation, a copy of which is attached hereto as an exhibit and incorporated by reference herein.

The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission (the “SEC”), as amended by the post-effective registration statement on Form S-8 POS filed February 5, 2016, (ii) the registration statement on Form S-8 (number 333-209403) of the registrant, filed with the SEC, and (iii) the registration statement on Form F-3 (333-207543) of the registrant, filed with the SEC, in each case to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

99.1	Press release: “Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne”
99.2	Foamix Pharmaceuticals Ltd. Investors Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FOAMIX PHARMACEUTICALS LTD. (Registrant)
By:	/s/ Ilan Hadar
	Name: Ilan Hadar
	Title: Chief Financial Officer

Date: May 3, 2017

2

EX-99.1

Exhibit 99.1

Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for

FMX101 in Moderate to Severe Acne

Pooled Analyses of Phase 3 Data Show Additional Statistically Significant Effects on Primary and Secondary Efficacy Endpoints

Commencement of 3^rd Phase 3 Trial Planned mid 2017; Submittal of NDA Planned in H2-2018

Conference Call and Live Webcast with Slides at 8:30am ET Tomorrow, May 2nd

Rehovot, Israel, and Bridgewater, NJ – May 1, 2017 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced results from additional analysis of the recently completed Phase 3 pivotal trials for its lead candidate FMX101 in moderate to severe acne.

Foamix has reviewed its regulatory strategy for FMX101.  Based on the knowledge gained from the results of the first two pivotal trials (Trials 04 and 05), the company intends to conduct a third U.S. Phase 3 Trial, beginning mid-year, in patients with moderate to severe acne.  If the results will be positive, this trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in the second half of 2018.

“The totality of the clinical efficacy results for FMX101, including the further analysis we conducted of the Phase 3 data, are positive.  Inconsistent results were noted in only one of the efficacy endpoints and the product appears to be safe and well tolerated,” said Dov Tamarkin, Ph.D., CEO of Foamix. “Based on our analysis of the efficacy results from Trials 04 and 05, we plan to conduct a third trial to validate the results, with the same co-primary endpoints and enrollment criteria but with a substantially increased sample size.  We intend to begin enrolling patients in this third trial mid-year.  If approved, we believe FMX101 will be the first FDA-approved topical minocycline treatment for moderate-to-severe acne, a skin disorder that affects millions of people with potentially significant psychological and social implications.”

Additional Phase 3 Analysis -- Pooled Data Statistically Significant for Both Co-Primary Efficacy Endpoints

Foamix previously announced topline data from two double-blind, randomized, placebo-controlled Phase 3 trials (Trials 04 and 05) that had investigated FMX101in a total of 961 patients with moderate-to-severe acne. Patients had been treated with either FMX101 (minocycline foam 4%) or vehicle foam once daily over 12 weeks.The results of the co-primary endpoints (absolute change in the number of inflammatory lesions and the proportion of patients achieving investigator global assessment (IGA) success at week 12) for trials 04 and 05 were presented separately.

The new analysis, presented below, reflects the pooled data results for the co-primary endpoints from the two trials.  Also presented are data from secondary efficacy endpoint analyses -- reduction of non-inflammatory lesion count at week 12, and percent changes in inflammatory lesion count at week 3, 6, 9 and 12.

As previously announced, FMX101 was generally safe and well tolerated with no drug-related serious adverse events identified.

Co-primary endpoint - Absolute change from baseline in inflammatory lesion count at week 12:

· Trial 04: reduction of 14.16 lesions (or -14.16) for FMX101 and reduction of 11.17 lesions (or -11.17) for the vehicle (p<0.01)

· Trial 05: -13.46 for FMX101 and -10.72 for vehicle (p<0.01)

· Pooled Analysis: Absolute change in inflammatory lesion count was -13.79 for the FMX101, 4% treatment group and -10.94 for vehicle (p=0.0001)

Co-primary endpoint - Proportion of patients with Investigator's Global Assessment (IGA) success at week 12:

· Trial 04:  IGA treatment success for FMX101, 4% treatment group was 8.09% versus 4.77% in vehicle (p=0.2178)

· Trial 05: IGA treatment success for FMX101, 4% treatment group was 14.67% versus 7.89% in vehicle (p<0.05)

· Pooled Analysis: IGA treatment success was 11.51% for FMX101, 4% treatment group and 6.34% for vehicle (p<0.05)

Additional Phase 3 Analyses – Results Statistically Significant for Secondary Efficacy Endpoints

Secondary efficacy endpoint - Percent change from baseline in inflammatory lesion count at weeks 3, 6, 9 and 12:

· Trial 04: reduction of 29% for FMX101 vs. reduction of 19% for vehicle, or  -29% vs. -19%, at week 3 (p<.001); -37% vs. -26% at week 6 (p<.001); -42% vs. -28% at week 9 (p<.0001); and -44% vs. -34% at week 12 (p<0.01)

· Trial 05: reduction of 34% for FMX101 vs. reduction of 21% for vehicle, or -34% vs. -21%, at week 3 (p<.0001); -39% vs. -27% at week 6 (p<.0001); -43% vs. -31% at week 9 (p<.001); and: -43% vs. -34% at week 12 (p<0.01)

Secondary efficacy endpoint – Absolute change from baseline in non-inflammatory lesion count at week 12

· Trial 04: reduction of 16.45 lesions (or -16.45) for the FMX101, 4% treatment group and reduction of 10.30 lesions (or -10.30) for the vehicle (p<0.01)

· Trial 05: -13.20 for the FMX101, 4% treatment group and -7.00 for the vehicle (p<0.05)

· Pooled Analysis: Absolute change in non-inflammatory lesion count was -14.76 for the FMX101, 4% treatment group and -8.64 for vehicle (p<0.01)

FMX101 Third Pivotal Trial (Trial 22) to Commence by Mid-Year

In order to achieve the necessary statistical power, compared with the prior Phase 3 trials, the target patient enrollment number has been increased to 1,500.  Patients will be randomized 1:1 to receive either FMX101 (minocycline foam 4%) or vehicle foam once daily over 12 weeks.  The co-primary efficacy endpoints will be identical to the prior Phase 3 trials: 1) mean change from baseline in the inflammatory lesion count, and 2) proportion of patients with IGA scores of “Clear” or “Almost Clear”, with improvement of at least two grades from baseline. The inclusion criteria will be consistent with the prior Phase 3 trials. The trial is planned to be conducted at approximately 80 clinical sites in the U.S.

Changes to Planned Phase 3 Trial Design for FMX103 in Papulopustular Rosacea

Foamix is also developing FMX103, minocycline foam 1.5%, a topical foam formulation of minocycline for the treatment of moderate-to-severe papulopustular rosacea. Based on the outcome of the Phase 3 studies for FMX101 and the increase in the number of patient to be enrolled to the third Phase 3 trial in acne, the company has also increased the sample size for the two planned Phase 3 studies for FMX103 in papulopustular rosacea.  The sample size is being increased from 600 patients per trial to 750 patients per trial, for a total of 1500 patients across the two trials.  As previously communicated, the company intends to commence the Phase 3 studies for FMX103 mid-year 2017.

Conference Call Information:

May 2, 2017 @ 8.30am EDT

Investors: 877-548-7911

International: 719-325-4769

Israel Investors: 1 80 925 8243

Conference ID:  8394096

Webcast: http://public.viavid.com/index.php?id=124227

Replays, Available through May 16 EDT

Toll-Free: 844-512-2921

International: 412-317-6671

Replay PIN: 8394096

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations.  Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.  Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital.  We discuss many of these risks in greater detail under the heading "Risk Factors" in our most recent Annual Report on Form 20-F (File No. 17625089) filed on February 21, 2017 and elsewhere in that Annual Report. Any forward-looking statements made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contact:	US Investor Relations
Ilan Hadar, CFO	Michael Rice
Foamix Pharmaceuticals Ltd.	LifeSci Advisors, LLC
+972-8-9316233	646-597-6979
ilan.hadar@foamixpharma.com	mrice@lifesciadvisors.com

EX-99.2

Exhibit 99.2

 Nasdaq: FOMX  FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe AcnePhase 3 Analysis & PlanMay 2017 

 Disclaimer  To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our product candidates by physicians and patients; (v) the timing or likelihood of regulatory filings and approvals; and (vi) our revenues under our agreements with our licensees, including Bayer, Allergan and Merz. Although we believe that the expectations reflected in the forward-looking statements are reasonable, various factors may cause differences between our expectations and actual results, including, but not limited to, unexpected safety or efficacy data, unexpected side effects observed during preclinical studies or in clinical trials, lower than expected enrollment rates in clinical trials, changes in expected or existing competition, changes in the regulatory environment for our product candidates and our need for future capital, the inability to protect our intellectual property, and the risk that we become a party to unexpected litigation or other disputes. You should read the documents filed by Foamix with the SEC, including our prospectuses, the Risk Factors set forth therein and the documents filed as exhibits to our registration statements, of which the prospectuses are a part, completely and with the understanding that our actual future results may be materially different from what we expect.  You may obtain those documents by visiting EDGAR on the SEC website at www.sec.gov. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the foam technology or product candidates of Foamix.  * 

 Phase 3 Pivotal Clinical Studies   *  Protocol FX2014-04 and Protocol FX2014-05  A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris 

 Phase 3: Design of Each Pivotal Study (x2)  Self-apply, once daily, in the evening, for 12 weeksInclusion criteriaAt least 20 inflammatory and 25 non-inflammatory lesionsIGA 6 point scale – Moderate or Severe (Grade 3 or 4) Co-Primary Efficacy EndpointsMean change from baseline in inflammatory lesion countProportion of subjects with IGA scores of “Clear” or “Almost Clear”, with improvement of at least 2 grades from baseline  *  12-week, randomized, double-blind, vehicle controlled, in subjects with moderate-to-severe acne; followed by 9 month open label safety extension  Week 12(End of treatment)  12 Months  Week 3  Week 6  Week 9  Double-blinded PhaseRandomized (2:1), double-blindN = 450  Minocycline foam 4% – 9 months of treatment  Open Label Safety Extension Subjects who complete one of the randomized, Phase 3 studies may enter the open-label phase  Minocycline Foam 4%Foam vehicle  Baseline 

 Acne Phase 3  *  Baseline Data  Total number of subjects: 466 (Study 04) 495 (Study 05)Mean age: 20.3 20.6Male/Female: M=42.9% F=57.1% M=41.4% F=58.6%Ethnicity: W=62.7% B=27.0% O=10.3% W=74.1% B=20.8% O=5.0%     Study 04  Study 04  Study 05  Study 05     FMX-101, 4%(N = 307)  Vehicle(N = 159)  FMX-101, 4%(N = 333)  Vehicle(N = 162)  Baseline Inflammatory Lesion Counts   Baseline Inflammatory Lesion Counts   Baseline Inflammatory Lesion Counts   Baseline Inflammatory Lesion Counts      Mean (SD)  32.2(8.4)  31.6(8.6)  31.6(8.6)  32.3(8.0)   Median   31  30  30  31   Range (min-max)  20-50  20-76  20-69  20-50  Baseline Non-inflammatory Lesion Counts   Baseline Non-inflammatory Lesion Counts   Baseline Non-inflammatory Lesion Counts   Baseline Non-inflammatory Lesion Counts      Mean (SD)  49.5(18.0)  46.5(16.6)  50.5(19.5)  50.9(19.9)  Baseline Total Lesion Counts   Baseline Total Lesion Counts   Baseline Total Lesion Counts   Baseline Total Lesion Counts      Mean (SD)  81.7(21.3)  78.1(19.7)  81.5(21.9)  83.1(23.2)  Baseline IGA Score, n (%)   Baseline IGA Score, n (%)   Baseline IGA Score, n (%)   Baseline IGA Score, n (%)      3 – Moderate  255(83.1)  137(86.2)  296(88.9)  148(91.4)   4 – Severe  52(16.9)  22(13.8)  37(11.1)  14(8.6) 

 P<.01*  P<.01*  *  *ANCOVA, Intent to Treat (ITT) Population, multiple imputation  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy ResultsReduction of Inflammatory Lesion Count at Week 12  In Study 04, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was -14.16 versus -11.17 in vehicle (p=0.0071) In Study 05, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was -13.46 versus -10.72 in vehicle (p=0.0058) In the Pooled Analysis, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was -13.79 versus -10.94 in vehicle (p=0.0001)  FMX101  Vehicle  P<.01*  n=640  n=321 

 P<.05*  P<.05*  P>0.21*  *  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy ResultsIGA Treatment Success at Week 12 [Score Clear (0) or Almost Clear (1)]  In Study 04, IGA Treatment Success for FMX101, 4% treatment group was 8.09% versus 4.77% in vehicle (p=0.2178) In Study 05, IGA Treatment Success for FMX101, 4% treatment group was 14.67% versus 7.89% in vehicle (p=0.0423) In the Pooled Analysis, IGA Treatment Success for FMX101, 4% treatment group was 11.51% versus 6.34% in vehicle (p=0.0188)  n=640  n=321  FMX101  Vehicle  *Cochran–Mantel–Haenszel test stratified by investigational site, Intent to Treat (ITT) population, multiple imputation 

 P<.05*  *  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Secondary Efficacy EndpointReduction of Non-Inflammatory Lesion Count at Week 12  In Study 04, absolute change in non-inflammatory lesion count for the FMX101, 4% treatment group was -16.45 versus -10.30 in vehicle (p=0.0042) In Study 05, absolute change in non-inflammatory lesion count for the FMX101, 4% treatment group was -13.20 versus -7.00 in vehicle (p=0.0320) In the Pooled Analysis, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was -14.76 versus -8.64 in vehicle (p=0.0011)  FMX101  Vehicle  P<.01*  n=640  n=321  *ANCOVA, Intent to Treat (ITT) Population, multiple imputation  P<.01* 

 Acne Phase 3 Secondary Efficacy Endpoint% Change in Inflammatory Lesion Count at Weeks 3, 6, 9 and 12^  *  Weeks  % Reduction of IL  Weeks  % Reduction of IL  ^ANCOVA, Intent to Treat (ITT) Population, multiple imputation  In Study 04, percent change in inflammatory lesion count for the FMX101, 4% treatment group at week 12 was -44% versus -34% in vehicle (p=0.0033) In Study 05, percent change in inflammatory lesion count for the FMX101, 4% treatment group at week 12 was -43% versus -34% in vehicle (p=0.0097) Statistical significance demonstrated at all timepoints (beginning at Week 3) for both Study 04 & 05  −44%  −34%  ‡P≤.01; †P ≤.001; *P ≤.0001  *  †  ‡  †  −43%  −34%  ‡  *  †  Study 04 - IL Count % Change     Study 05 - IL Count % Change  * 

 FMX101 Phase 3 Patient Satisfaction Questionnaire at Week 12, ITT Population (Observed-Cases, n=534)  *  Overall, how satisfied are you with this product?  Study 04 & Study 05 Pooled Analysis  How satisfied are you with this product compared to other products you have previously used for acne, such as gels and creams?  Scale 1- Very Satisfied2- Satisfied3- Somewhat Satisfied4- Dissatisfied5- Very Dissatisfied  ~75% of subjects satisfied or very satisfied with FMX101  ~70% of subjects were satisfied or very satisfied with FMX101 vs. other topical acne therapies 

 FMX101 Phase 3 Patient Satisfaction (cont.)Questionnaire at Week 12, ITT Population (Observed-Cases, n=534)  *  Study 04 & Study 05 Pooled Analysis  How satisfied are you with how easy this product is to use?  How satisfied are you with how this product feels on your skin after treatment?  Scale 1- Very Satisfied2- Satisfied3- Somewhat Satisfied4- Dissatisfied5- Very Dissatisfied  >80% of patients were satisfied or very satisfied with the ease of use of FMX101   Only 16% of patients were dissatisfied or very dissatisfied with the product feel of FMX101 

 FMX101 Phase 3 Results Summary  Totality of efficacy results for FMX101 in Ph3 are positive, with inconsistent results found in only one endpoint (IGA 0/1 Treatment Success in Study 04) Pooled analysis of IGA 0/1 Treatment Success is statistically significant % Change in inflammatory lesion count is statistically significant in Study 04 and Study 05 at all timepoints (beginning at Week 3)Non-inflammatory lesion count reduction at Week 12 is statistically significant in Study 04 and Study 05 Overall high level of patient satisfaction with FMX101   * 

 FMX101 3rd Phase 3 Study DesignStudy FX2017-22  13  12-week, randomized, double-blind, vehicle controlled, in subjects with moderate-to-severe acne  Week 12(End of treatment)  Week 3  Week 6  Week 9    Double-blinded Study (-22)Randomized (1:1), double-blindN=1,500  Study commencement expected Mid-2017; Topline results expected Mid-2018            Minocycline Foam 4%Foam vehicle  Week 3  1 US Study, 1,500 subjects, ~80 sites, >9 years of ageSelf-apply, once daily, for 12 weeksInclusion CriteriaAt least 20 inflammatory and 25 non-inflammatory lesionsIGA 5 point scale – Moderate to Severe (Grade 3 or 4)Co-primary Efficacy Endpoints:Mean change from baseline in inflammatory lesion countProportion of subjects with IGA scores of “Clear” or “Almost Clear”, with improvement of at least 2 grades from baselineSafety Evaluations: AEs, physical exams, vitals, dermal tolerability, erythema assessments, labs 

 FMX103 Phase 3 Study Design Studies FX2016-11, FX2016-12 & FX2016-13  14  12-week, randomized, double-blind, vehicle controlled, in subjects with moderate-to-severe papulopustular rosacea; followed by 9 month open label safety extension  Week 12 (End of treatment)  12 Months  Week 2  Week 4  Week 8      Double-blinded Study (-11,-12)Randomized (2:1), double-blindN=750 (X2)    Minocycline Foam 1.5%Foam vehicle    Minocycline foam 1.5% – 9 months of treatment  Open Label Safety Extension Study (-13) Subjects who complete one of the randomized, Phase 3 studies may enter the open-label study  2 US Studies, ~80 sites, 750 subjects per study (N=1,500 subjects), >18 years of ageSelf-apply, once daily, for 12 weeksInclusion Criteria15 to 75 inflammatory lesions IGA 5 point scale – Moderate to Severe (Grade 3 or 4)Co-primary Efficacy Endpoints:Mean change from baseline in inflammatory lesion countProportion of subjects with IGA scores of “Clear” or “Almost Clear”, with improvement of at least 2 grades from baselineSafety Evaluations: AEs, physical exams, vitals, dermal tolerability, erythema assessments, labs  Study commencement expected Mid-2017; Topline results expected Mid-2018 

                                 Target Milestones  *  TLR (Studies 04 & 05)  Mar 27  3rd Ph3 DB (Study 22)  Ph3 LTS  3rd Ph3 TLR  NDA  PDUFA  2017  2020  H12017  H2  H1 2018  H2  H1 2019  H2  H1 2020  H2  FMX101, 4% (Acne)  FMX103, 1.5% (Rosacea)  TLR = Topline Results*Actual timelines may vary 

 Summary  Totality of efficacy results for FMX101 in Ph3 are positive, with inconsistent results found in only one endpoint (IGA 0/1 Treatment Success in Study 04) Pooled analysis of IGA 0/1 Treatment Success is statistically significant Non-inflammatory lesion count reduction is statistically significant in Study 04 and Study 05% Change in inflammatory lesion count is statistically significant in Study 04 and Study 05 at all timepoints (beginning at Week 3)Overall high level of patient satisfaction with FMX101 Commencement of 3rd Ph3 study expected mid 2017Ongoing communications with FDAFMX101 long-term safety study expected to be completed year end FMX101 NDA filing expected H2 2018FMX103 Ph3 first patient enrolled expected mid year Sufficient capital to support development of FMX101 and FMX103, into 2019  *